Document is current
Any future updates will be listed below
-
Authors
Li, Zhengxin
Sun, Xin
Zhao, Zhimin
Yang, Qiang
Ren, Yayun
Teng, Xiao
Tai, Dean C. S.
Wanless, Ian R.
Schattenberg, Jörn M.
Liu, Chenghai
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81730109, 82274305, 82305200, 82374122)
National Natural Science Foundation of China (81730109, 82274305, 82305200, 82374122)
National Natural Science Foundation of China (81730109, 82274305, 82305200, 82374122)
National Natural Science Foundation of China (81730109, 82274305, 82305200, 82374122)
National Science and Technology Major Project (2018ZX10302204)
National Science and Technology Major Project (2018ZX10302204)
Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 20 January 2025
First Online: 24 January 2025
Declarations
:
: Written informed consent was obtained from all the participants prior to the enrollment of this study. To protect patient privacy, the pathology number serves as a unique identifier. The study have been performed in accordance with the Declaration of Helsinki. Approval Number: 2015-445-73-01, Institutional Review Board of Shuguang Hospital.
: J.M.S. reports Consultant: Akero, Alentis Therapeutics, Astra Zeneca, Apollo Endosurgery, 89Bio, Boehringer Ingelheim, GSK, Ipsen, Inventiva Pharma, Madrigal, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers. Research Funding: Boehringer Ingelheim, Siemens Healthcare GmbH. Stock Options: AGED diagnostics, Hepta Bio. Speaker Honorarium: Gilead Sciences, Advanz, Echosens, MedPublico GmbH. The other authors do not have any disclosures to report.
